Piramal Lifesciences hits upper circuit

MUMBAI: Shares of Piramal Lifesciences hit the upper circuit limit Wednesday following the company���s announcement that it has received regulatory approval by the Drug Controller General of India to conduct two Phase I/II combination studies for its cancer molecule P276 for pancreatic, and head and neck cancer.

The objective of both studies is to identify the right doses of P276 to be used in combination with chemotherapeutic drugs and to evaluate the benefit of the same in pancreatic and head and neck cancer patients, the company said in a note to the exchanges.

At 10:30 am, the company���s shares surged 4.99 per cent to Rs 51.50 on the BSE.